Full video transcriptClick to expand
Auto-generated transcript of @epicgenetics's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I actually bumped into Mike Thurston at the Health Optimization Summer and he was telling me about this
- 0:04therapy he did with Dr. O'Connor and yeah it costs around $25,000 when Brian Johnson documented it
- 0:12about six months ago and he gained six kilos while reversing his biological age which is very
- 0:18hard to do to add actual muscle mass and decrease your pace of aging at the same time.
Follistatin gene therapy for bodybuilding: hype vs. human data
Quick answer
Follistatin gene therapy using AAV vectors has been studied in small trials for muscular dystrophy, not healthy athletic populations, and has not received FDA approval for enhancement use. Claims of simultaneous muscle gain and biological age reversal in a single healthy individual lack peer-reviewed support and rely entirely on self-reported outcomes. The risk profile of AAV-delivered gene therapy in healthy adults, including immune response and off-target effects, remains poorly characterized outside controlled research settings.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 4 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Follistatin gene therapy for bodybuilding: hype vs. human data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Follistatin gene therapy for bodybuilding: hype vs. human data should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Follistatin gene therapy for bodybuilding: hype vs. human data" from Tony Pemberton. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Follistatin gene therapy using AAV vectors has been studied in small trials for muscular dystrophy, not healthy athletic populations, and has not received FDA approval for enhancement use.
The reason this review is not generic is the source wording and the canonical claim label "peptides follistatin gene therapy revolutionizes bodybuilding mikethu." In this clip, the useful excerpt is: "I actually bumped into Mike Thurston at the Health Optimization Summer and he was telling me about this therapy he did with Dr." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against NAD+ metabolism and its roles in cellular processes during ageing (2021), Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women (2021), and Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults (2018), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Follistatin gene therapy using AAV vectors has been studied in small trials for muscular dystrophy, not healthy athletic populations, and has not received FDA approval for enhancement use.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Follistatin gene therapy using AAV vectors has been studied in small trials for muscular dystrophy, not healthy athletic populations, and has not received FDA approval for enhancement use. Claims of simultaneous muscle gain and biological age reversal in a single healthy individual lack peer-reviewed support and rely entirely on self-reported outcomes. The risk profile of AAV-delivered gene therapy in healthy adults, including immune response and off-target effects, remains poorly characterized outside controlled research settings.
- Follistatin inhibits myostatin and promotes muscle growth in animal models, but human RCT data in healthy adults does not exist for this application.
- The only published human trials of AAV-follistatin therapy involve muscular dystrophy patients, not athletes (Rodino-Klapac et al., 2015, Molecular Therapy).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Follistatin inhibits myostatin and promotes muscle growth in animal models, but human RCT data in healthy adults does not exist for this application.
- The only published human trials of AAV-follistatin therapy involve muscular dystrophy patients, not athletes (Rodino-Klapac et al., 2015, Molecular Therapy).
- AAV-based gene therapy is not FDA-approved for athletic or longevity enhancement and carries risks including immunogenicity and off-target effects documented in clinical literature.
- Bryan Johnson's reported outcomes are self-documented with no peer-reviewed methodology, no control group, and no independent replication.
- Myostatin inhibition strategies have consistently underperformed in human clinical translation compared to animal model results (Kalinkovich and Livshits, 2021, Ageing Research Reviews).
- A $25,000 price tag and influencer endorsement are not substitutes for clinical trial data, and anyone considering this intervention should consult a physician familiar with gene therapy risk profiles.
- Gene therapy and peptide therapy are categorically different interventions. Do not treat a TikTok anecdote as a treatment protocol.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @epicgenetics actually say?
The creator claimed to have spoken with fitness influencer Mike Thurston, who allegedly underwent follistatin gene therapy with a Dr. O'Connor, costing "around $25,000." They also referenced Bryan Johnson as having documented the treatment about six months ago, and said Johnson "gained six kilos while reversing his biological age." The core claim is that one intervention can simultaneously build significant muscle and slow aging. That is a very big claim, and the sourcing here is essentially gossip at a health conference.
To be fair, follistatin is a real protein. It inhibits myostatin, which is the brake pedal on muscle growth. The biology is legitimate. The leap from "the biology is real" to "this $25,000 therapy works as advertised in humans" is enormous, and this video does not clear that bar.
Does the science back this up?
Partially, but not in the way the video implies. Follistatin's role in muscle regulation is well-documented in animals. Blocking myostatin in mice and cattle produces dramatic muscle hypertrophy. Human evidence is far thinner and largely confined to rare disease research, not healthy-athlete optimization.
A 2015 paper by Rodino-Klapac et al. in Molecular Therapy looked at follistatin gene therapy in Becker muscular dystrophy patients using an AAV vector. They saw modest functional improvements, but this was a diseased population with a clear medical need, not bodybuilders looking for an edge. More recently, a 2021 review by Kalinkovich and Livshits in Ageing Research Reviews noted that myostatin inhibition strategies have repeatedly underperformed in clinical translation compared to animal models. The six-kilogram muscle gain figure attributed to Bryan Johnson has no peer-reviewed citation attached to it. It appears to come from self-reported content, which is not a study.
What did they get wrong (or right)?
They got the basic biology directionally right. Follistatin does inhibit myostatin. Myostatin inhibition is associated with increased muscle mass in animal models. That part is not in dispute.
What they got wrong, or at minimum presented irresponsibly, is the implied efficacy and safety in healthy humans. AAV-based gene therapy carries real risks: immunogenicity, off-target insertion, and liver toxicity have all been documented in vector-based therapies (Nathwani et al., 2014, NEJM). Presenting this as something a fitness influencer casually does at a clinic for $25,000, with the main evidence being a conference conversation and Bryan Johnson's self-documentation, is not responsible health communication.
- The "reversing biological age" claim is attached to no published methodology or control group.
- Six kilograms of lean mass in a short window would be extraordinary even with pharmaceutical-grade interventions.
- The $25,000 price point is unverified and framing cost as a credibility signal is a red flag.
What should you actually know?
Gene therapy is not peptide therapy. This is worth saying clearly. Peptides like follistatin-related compounds are one thing. Viral vector gene delivery, which is what AAV-based follistatin therapy actually involves, is a different category of medical intervention entirely. It is not reversible. It is not approved by the FDA for this application. And it is not something any clinic should be offering for athletic enhancement outside of a clinical trial.
The legitimate research on follistatin is interesting and ongoing. But the gap between "interesting animal data and rare disease trials" and "go pay $25,000 at a longevity clinic" is enormous. Anyone seeing this video and thinking this is a reasonable next step for their fitness goals should know that no regulatory body has cleared this use, no large randomized controlled trial in healthy adults exists, and the risk profile is genuinely unknown at this scale of use.
If you are interested in peptide-based recovery and optimization through a regulated platform, that is a very different conversation from gene therapy. Do not conflate them based on a TikTok anecdote.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Tony Pemberton · TikTok creator
9.9K views on this video
Follistatin Gene Therapy REVOLUTIONIZES Bodybuilding! #mikethurston #follistatin #follistatingenetherapy #bodybuilding #peptide #peptidetherapy #muscle #gym #bryanjohnson #longevity #epigenetics
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about follistatin inhibits myostatin?
Follistatin inhibits myostatin and promotes muscle growth in animal models, but human RCT data in healthy adults does not exist for this application.
What does the video say about the only published human trials of aav-follistatin therapy involve muscular?
The only published human trials of AAV-follistatin therapy involve muscular dystrophy patients, not athletes (Rodino-Klapac et al., 2015, Molecular Therapy).
What does the video say about aav-based gene therapy?
AAV-based gene therapy is not FDA-approved for athletic or longevity enhancement and carries risks including immunogenicity and off-target effects documented in clinical literature.
What does the video say about bryan johnson's reported outcomes?
Bryan Johnson's reported outcomes are self-documented with no peer-reviewed methodology, no control group, and no independent replication.
What does the video say about myostatin inhibition strategies have consistently underperformed in human clinical translation?
Myostatin inhibition strategies have consistently underperformed in human clinical translation compared to animal model results (Kalinkovich and Livshits, 2021, Ageing Research Reviews).
What does the video say about a $25,000 price tag?
A $25,000 price tag and influencer endorsement are not substitutes for clinical trial data, and anyone considering this intervention should consult a physician familiar with gene therapy risk profiles.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Tony Pemberton, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.